136 related articles for article (PubMed ID: 11032928)
1. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer.
Silén A; Rizvi SS; Letocha H; Lennernäs B; Wiklund B
Oncol Rep; 2000; 7(6):1269-74. PubMed ID: 11032928
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.
Heicappell R; Schostak M; Müller M; Miller K
Scand J Clin Lab Invest; 2000 Jul; 60(4):275-82. PubMed ID: 10943597
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
4. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
[TBL] [Abstract][Full Text] [Related]
5. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma.
Sánchez-Carbayo M; Ciudad J; Urrutia M; Navajo JA; Orfao A
Cancer; 2001 Dec; 92(11):2811-9. PubMed ID: 11753954
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the diagnostic accuracy of UBC
Styrke J; Henriksson H; Ljungberg B; Hasan M; Silfverberg I; Einarsson R; Malmström PU; Sherif A
Scand J Urol; 2017 Aug; 51(4):293-300. PubMed ID: 28422550
[TBL] [Abstract][Full Text] [Related]
9. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Vigl EE; Marberger M; Pycha A
Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
[TBL] [Abstract][Full Text] [Related]
11. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
12. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
13. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder.
Sumi S; Arai K; Kitahara S; Yoshida KI
Clin Chim Acta; 2000 Jun; 296(1-2):111-20. PubMed ID: 10807975
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Egarter Vigl E; Marberger M; Pycha A
Urology; 2000 Aug; 56(2):228-31. PubMed ID: 10925083
[TBL] [Abstract][Full Text] [Related]
16. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer.
Mungan NA; Vriesema JL; Thomas CM; Kiemeney LA; Witjes JA
Urology; 2000 Nov; 56(5):787-92. PubMed ID: 11068302
[TBL] [Abstract][Full Text] [Related]
17. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
18. Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.
Gacci M; Serni S; Lapini A; Giubilei G; Dal Canto M; Paladini S; Curotto A; Gallo F; Carmignani G; Carini M
Arch Ital Urol Androl; 2006 Mar; 78(1):5-10. PubMed ID: 16752880
[TBL] [Abstract][Full Text] [Related]
19. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
20. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
Urology; 1999 Oct; 54(4):656-61. PubMed ID: 10510924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]